FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
BriaCell Therapeutics Corp. Stock AnalysisComprehensive stock analysis for BriaCell Therapeutics Corp. (BCT.TO) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisBCT.TO
BCT.TO
BriaCell Therapeutics Corp.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
BCT.TO
Home🔹Stocks🔹BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp.

BCT.TO•TSX

BriaCell Therapeutics Corp.

BCT.TO•TSX
Market cap
$9.15M
Sentiment

Your view on BCT.TO

Mkt Cap
$9.15M
Sentiment
Your view
BCT.TO
BriaCell Therapeutics Corp.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
BCT.TO
Company Overview

Overview

What the company does, where it operates, and who runs it.

About BriaCell Therapeutics Corp.

Industry
Biotechnology
Sector
Healthcare
CEO
William V. Williams FCPA,
Headquarters
Bellevue Centre, West Vancouver, BC, CA
Industry
Biotechnology
Sector
Healthcare
CEO
William V. Williams FCPA,
Headquarters
Bellevue Centre, West Vancouver, BC, CA
Description

BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients' HLA types. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to conduct preclinical studies to develop and test Bria-OTS cellular immunotherapy as a treatment for cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News